Mashayekh-Poul Romina, Azimzadeh-Irani Maryam, Masoomi-Nomandan Seyedeh Zeinab
Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Mol Biol Res Commun. 2023;12(3):95-107. doi: 10.22099/mbrc.2023.47147.1822.
The human epidermal growth factor receptor (EGFR/ErbB) family consists of four members (ErbB1-4) and belongs to the superfamily of receptor tyrosine kinases (RTKs). The ErbB family members participate in multiple cellular pathways and are the key players in several cancers (brain, breast, lung etc.). Activation of these family members depends on their extracellular domains forming back-to-back hetero/homo dimers. Moreover, dimers are glycosylated, which is a crucial post-translational modification that affects the conformation and function of the protein. Here, molecular modeling and molecular docking are used to comprehensively investigate the dimerization mechanism in glycosylated back-to-back active dimer formation in the entire ErbB receptors for the first time. Results showed that 21 out of 37 clusters of active back-to-back dimers formed by all family members are through heterodimerization. Including; ErbB1-ErbB3/ErbB4, ErbB2-ErbB3/ErbB4 and ErbB3-ErbB4. Ranking ErbB2-ErbB3 as the most stabilized back-to-back dimeric construct. While glycan arrangements favor both homo/hetero dimerization at the dimeric interfaces, it promotes heterodimerization by stabilizing and packing the ligand binding sites of EGFR and ErbB2 respectively. These findings pave the path to future heterodimeric interface/glycan targeting rational anti-cancer drug designs for ErbB receptors.
人表皮生长因子受体(EGFR/ErbB)家族由四个成员(ErbB1 - 4)组成,属于受体酪氨酸激酶(RTK)超家族。ErbB家族成员参与多种细胞途径,是几种癌症(脑癌、乳腺癌、肺癌等)中的关键角色。这些家族成员的激活取决于其细胞外结构域形成背对背的异源/同源二聚体。此外,二聚体是糖基化的,这是一种关键的翻译后修饰,会影响蛋白质的构象和功能。在此,首次使用分子建模和分子对接全面研究整个ErbB受体中糖基化背对背活性二聚体形成的二聚化机制。结果表明,所有家族成员形成的37个活性背对背二聚体簇中有21个是通过异源二聚化形成的。包括:ErbB1 - ErbB3/ErbB4、ErbB2 - ErbB3/ErbB4和ErbB3 - ErbB4。将ErbB2 - ErbB3列为最稳定的背对背二聚体结构。虽然聚糖排列有利于在二聚体界面处进行同源/异源二聚化,但它分别通过稳定和填充EGFR和ErbB2的配体结合位点来促进异源二聚化。这些发现为未来针对ErbB受体的异源二聚体界面/聚糖靶向合理抗癌药物设计铺平了道路。